Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

FT819

Cell therapy (CAR-T) · Kills target cells, directed at CD19 · developed by Fate Therapeutics

Phase 2 Most advanced trial
FATE Developer
1 Registered trials

What is FT819?

FT819 is an off-the-shelf allogeneic T-cell therapy derived from an induced pluripotent stem cell line, engineered to express a CD19-directed chimeric antigen receptor with CD28 and CD3-zeta signaling domains. The CAR T-cells bind CD19-expressing cells and lyse them, and the T-cell receptor is eliminated to reduce the risk of graft versus host disease. It is being studied in lupus nephritis and systemic lupus erythematosus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-T)
Targets
CD19 (antigen)
Mechanism
Kills target cells, directed at CD19
Therapy area
Immunology
Developer
Fate Therapeutics (FATE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07570862 Phase 2 Lupus Nephritis Recruiting FATE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lupus NephritisLupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IVSLE - Systemic Lupus ErythematosusSystemic Lupus Erythematosus

Other drugs acting on CD19

More from Fate Therapeutics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.

Follow FATE, the company behind FT819

See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

FATE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.